-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA awards Palvella third-year orphan grant funding for QTORIN rapamycin Phase 3 SELVA trial

PUBT·09/28/2026 11:30:23
Listen to the news
FDA awards Palvella third-year orphan grant funding for QTORIN rapamycin Phase 3 SELVA trial
  • Palvella Therapeutics received a third year of FDA Orphan Products Development grant funding for its Phase 3 SELVA program.
  • Funding supports the SELVA trial and open-label extension of QTORIN 3.9% rapamycin gel for microcystic lymphatic malformations.
  • The company completed its rolling NDA submission in August 2026, targeting a potential US launch in H1 2027 if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834661) on September 28, 2026, and is solely responsible for the information contained therein.